SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Electra Therapeutics, Inc. (Name of Issuer)

Common Stock, $0.0001 par value per share (Title of Class of Securities)

(CUSIP Number)

09/21/2026 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Redmile Group, LLC
2	Check the appropriate box if a member of a Group (see instructions)   (a)   (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	5 Sole Voting Power 0.00 6 Shared Voting Power 5,462,881.00 7 Sole Dispositive Power 0.00 8 Shared Dispositive Power 5,462,881.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 5,462,881.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11	Percent of class represented by amount in row (9) 8.7 %
12	Type of Reporting Person (See Instructions) IA, OO

Comment for Type of Reporting Person:  The information in Item 4 relating to the shares of common stock, $0.0001 par value per share, of the Issuer (the "Common Stock") that are or may be deemed beneficially owned by Redmile Group, LLC and the calculation of the percent of such class of securities is incorporated by reference herein.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Jeremy C. Green
2	Check the appropriate box if a member of a Group (see instructions)   (a)   (b)
3	Sec Use Only
4	Citizenship or Place of Organization UNITED KINGDOM
Number of Shares Beneficially Owned by Each Reporting Person With:	5 Sole Voting Power 0.00 6 Shared Voting Power 5,462,881.00 7 Sole Dispositive Power 0.00 8 Shared Dispositive Power 5,462,881.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 5,462,881.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11	Percent of class represented by amount in row (9) 8.7 %
12	Type of Reporting Person (See Instructions) HC, IN

Comment for Type of Reporting Person:  The information in Item 4 relating to the shares of Common Stock that are or may be deemed beneficially owned by Jeremy Green and the calculation of the percent of such class of securities is incorporated by reference herein.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Redmile Biopharma Investments II, L.P.
2	Check the appropriate box if a member of a Group (see instructions)   (a)   (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	5 Sole Voting Power 0.00 6 Shared Voting Power 4,796,215.00 7 Sole Dispositive Power 0.00 8 Shared Dispositive Power 4,796,215.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 4,796,215.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11	Percent of class represented by amount in row (9) 7.6 %
12	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person:  The information in Item 4 relating to the shares of Common Stock that are or may be deemed beneficially owned by Redmile Biopharma Investments II, L.P. and the calculation of the percent of such class of securities is incorporated by reference herein.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Electra Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 230 E. Grand Avenue Suite S-100 South San Francisco, CA 94080
Item 2.
(a)	Name of person filing: Redmile Group, LLC Jeremy C. Green Redmile Biopharma Investments II, L.P.
(b)	Address or principal business office or, if none, residence: Redmile Group, LLC 900 Larkspur Landing Circle, Suite 270 Larkspur, California 94939 Jeremy C. Green c/o Redmile Group, LLC (NY Office) 45 W. 27th Street, Floor 11 New York, NY 10001 Redmile Biopharma Investments II, L.P. c/o Redmile Group, LLC 900 Larkspur Landing Circle, Suite 270 Larkspur, California 94939
(c)	Citizenship: Redmile Group, LLC: Delaware Jeremy C. Green: United Kingdom Redmile Biopharma Investments II, L.P.: Delaware
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.:
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),        please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Redmile Group, LLC - 5,462,881 (1) Jeremy C. Green - 5,462,881 (1) Redmile Biopharma Investments II, L.P. - 4,796,215 (2)
(b)	Percent of class: Redmile Group, LLC - 8.7% (3) Jeremy C. Green - 8.7% (3) Redmile Biopharma Investments II, L.P. - 7.6% (3)  %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Redmile Group, LLC - 0 Jeremy C. Green - 0 Redmile Biopharma Investments II, L.P. - 0
	(ii) Shared power to vote or to direct the vote: Redmile Group, LLC - 5,462,881 (1) Jeremy C. Green - 5,462,881 (1) Redmile Biopharma Investments II, L.P. - 4,796,215 (2)
	(iii) Sole power to dispose or to direct the disposition of: Redmile Group, LLC - 0 Jeremy C. Green - 0 Redmile Biopharma Investments II, L.P. - 0
	(iv) Shared power to dispose or to direct the disposition of: Redmile Group, LLC - 5,462,881 (1) Jeremy C. Green - 5,462,881 (1) Redmile Biopharma Investments II, L.P. - 4,796,215 (2) (1) All of such shares of Common Stock are directly owned by certain investment vehicles, including Redmile Biopharma Investments II, L.P. ("RBI II"), for which Redmile is the investment manager (the "Redmile Funds"). Redmile may be deemed to beneficially own these securities in its capacity as their investment manager with discretion to vote and dispose of all shares of Common Stock held by the Redmile Funds. Mr. Green also may be deemed to beneficially own these securities as the principal of Redmile. Redmile and Mr. Green each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest in such securities, if any. (2) All of such shares of Common Stock are directly owned RBI II. (3) Percentage based on 62,766,955 shares of Common Stock outstanding immediately after the initial public offering, as reported in the Issuer's Prospectus dated September 17, 2026 filed with the SEC on September 18, 2026.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See the response to Item 4.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE
	After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Redmile Group, LLC

Signature: /s/ Jeremy C. Green Name/Title: Managing Member Date: 09/28/2026

Jeremy C. Green

Signature: /s/ Jeremy C. Green Name/Title: Jeremy C. Green Date: 09/28/2026

Redmile Biopharma Investments II, L.P.

Signature: /s/ Jeremy C. Green Name/Title: Managing Member of Redmile Group, LLC, Managing Member of Redmile Biopharma Investments II (GP), LLC, General Partner of Redmile Biopharma Investments Date: 09/28/2026

Exhibit Information

Exhibit 99.1 - Joint Filing Agreement

Exhibit 99.1

Joint Filing Agreement

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001 par value per share, of Electra Therapeutics, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.

The undersigned further agree that each party hereto is responsible for the timely filing of the Schedule 13G, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has a reason to believe that such information is inaccurate.

It is understood and agreed that a copy of this Joint Filing Agreement shall be attached as an exhibit to the Schedule 13G, filed on behalf of each of the parties hereto.

IN WITNESS WHEREOF, each of the undersigned has executed this Joint Filing Agreement as of September 28, 2026.